Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients?
Statins inhibit 3-hydroxyl-3-methylglutaryl coenzyme A reductase, an enzyme crucial to cholesterol synthesis. Drugs of this class reduce the risk of coronary heart disease and stroke, in large part through lipid modulation. Emerging evidence indicates that statins have additional modes of action. These actions, which encompass modification of endothelial function, plaque stability, thrombus formation and inflammatory pathways, are widely referred to as 'pleiotropic effects'. These pleiotropic effects indicate that the therapeutic potential of statins might extend beyond cholesterol lowering and cardiovascular disease to other inflammatory disorders or conditions such as transplantation, multiple sclerosis, rheumatoid arthritis and chronic kidney disease. Experimental and clinical data provide evidence to support these broader applications of statins; however, more large-scale trials are needed to clarify the therapeutic benefit.
Steffens
Sabine
S
Division of Cardiology, Department of Medicine, University Hospital, Foundation for Medical Research, Geneva, Switzerland.
Mach
François
F
D000818:Animals; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002908:Chronic Disease; D004195:Disease Models, Animal; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007107:Immune System / Q000187:drug effects*; D007165:Immunosuppression Therapy; D007674:Kidney Diseases / Q000517:prevention & control*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors